Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
VAL-083 (Dianhydrogalactitol)
DRUG
2 trials
Sponsors
Kintara Therapeutics, Inc.
Conditions
Brain Cancer
GBM
Glioblastoma
Glioblastoma Multiforme
Glioma
Phase 1
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Completed
NCT01478178
Kintara Therapeutics, Inc.
Brain Cancer, GBM, Glioblastoma +2
Start: 2011-10-31
End: 2016-10-31
Updated: 2025-08-29
Phase 2
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Completed
NCT03050736
Kintara Therapeutics, Inc.
Brain Cancer, GBM, Glioblastoma +2
Start: 2017-12-17
End: 2024-12-30
Updated: 2025-09-04
Related Papers
VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study.
2025-12-12
P11.41.B PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM: CASE STUDY REPORTS
Neuro-Oncology
2023-09-01
CTNI-32. PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM
Neuro-Oncology
2022-11-01
SYST-11 PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM
Neuro-Oncology Advances
2022-08-01
1 citations
CTNI-21. PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM
Neuro-Oncology
2021-11-02
SYST-05. PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM
Neuro-Oncology Advances
2021-09-21
1 citations
Abstract CT172: Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM
Cancer Research
2021-07-01
1 citations
CTNI-76. PHASE 2 CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM
Neuro-Oncology
2020-11-01
Abstract 5231: Dianhydrogalactitol (VAL-083) exhibits strong efficacy in GBM tumors with different (epi)genetic background and treatment history
Cancer Research
2020-08-15
3 citations
Abstract CT273: Phase 2 trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated glioblastoma
Cancer Research
2020-08-15
ACTR-06. CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM: HALF-WAY REPORT
Neuro-Oncology
2019-11-01
1 citations
Abstract CT116: Phase I/II study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma
Cancer Research
2019-07-01
1 citations
Abstract CT116: Phase I/II study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma
Clinical Trials
2019-07-01
Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report
Glioma
2019-01-01
12 citations
ACTR-71. PHASE 1/2 STUDY OF DIANHYDROGALACTITOL (VAL-083) WITH RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED, MGMT-UNMETHYLATED GLIOBLASTOMA
Neuro-Oncology
2018-11-01
1 citations
Abstract CT168: Phase I/II study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed glioblastoma, MGMT-unmethylated
Cancer Research
2018-07-01
48 Phase 2 studies of dianhydrogalactitol (VAL-083) in patients with glioblastoma, MGMT-unmethylated
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
2018-06-01
1 citations
Dianhydrogalactitol in bevacizumab-refractory GBM: Further analysis of a phase 1-2 trial.
Journal of Clinical Oncology
2018-05-20
3 citations
ACTR-50. CLINICAL TRIALS WITH DIANHYDROGALACTITOL (VAL-083) IN MGMT-UNMETHYLATED GLIOBLASTOMA
Neuro-Oncology
2017-11-01
Abstract CT074: Phase I/II study of VAL-083 in patients with recurrent glioblastoma
Cancer Research
2016-07-15
7 more papers not shown